Yes, humans can get kennel cough from dogs, but it is uncommon and almost always mild. The canine respiratory complex is caused by several agents, and only one of them, the bacterium Bordetella bronchiseptica, is a recognized human pathogen. When people are infected, they typically develop a lingering dry cough, low fever, and nasal congestion 3 to 10 days after exposure. Most cases resolve without antibiotics in 1 to 3 weeks. Severe disease is rare and clusters in immunocompromised people, infants, and those with chronic lung disease. The more common viral causes, including canine parainfluenza and canine adenovirus type 2, are not known to infect humans, so a cough after contact with a sick dog is usually coincidental.
What "Kennel Cough" Actually Is at the Pathogen Level
Kennel cough is not one disease. It is a clinical syndrome, also called canine infectious tracheobronchitis, defined by a harsh, honking cough that appears 2 to 10 days after exposure to a crowded dog setting. The term describes a symptom pattern, not a single organism.
At least five pathogens circulate in the mix. The two most common are Bordetella bronchiseptica, a gram-negative bacterium, and canine parainfluenza virus. Mycoplasma cynos, canine adenovirus type 2, and canine respiratory coronavirus are frequent co-travelers. In severe or chronic cases, Streptococcus zooepidemicus has appeared in outbreaks in shelter populations.
The reason "kennel cough" is a poor name for a human risk assessment is that each agent has a different host range. A virus that cannot bind human respiratory receptors poses zero risk regardless of how much a person is exposed. The only agent with a well-documented human case record is B. bronchiseptica.
In plain terms: kennel cough is a bundle of bugs, and only one of those bugs regularly makes the jump to people.
The Mechanism: How Bordetella bronchiseptica Crosses Species
B. bronchiseptica is a close relative of Bordetella pertussis, the cause of whooping cough, and Bordetella parapertussis. The three share much of their genetic toolkit for attaching to airway cells. That shared biology is the mechanism behind cross-species infection.
The bacterium uses filamentous hemagglutinin and pertactin to bind ciliated epithelial cells lining the trachea and bronchi. It then releases tracheal cytotoxin, which paralyzes and kills those cilia. With the cilia out of action, mucus and debris accumulate, and the cough reflex fires repeatedly. This is why the cough is dry, persistent, and often worse at night.
B. bronchiseptica carries a type III secretion system that injects effector proteins into host immune cells, dampening the early inflammatory response. This buys the bacterium 3 to 7 days before adaptive immunity mounts a defense. The incubation window in humans mirrors the canine window closely.
The critical constraint is receptor compatibility. The bacterium binds human airway cells less efficiently than canine cells. Laboratory binding studies suggest a 10- to 100-fold lower attachment efficiency on human tissue, which explains why human infection is uncommon even after heavy exposure. That figure is an estimate from in vitro work, not a clinical threshold, and should be treated as directional rather than precise.
How Often It Actually Happens: Quantified Human Risk
Human B. bronchiseptica infection is reportable in no US jurisdiction, so no national case count exists. The best available estimate comes from case series and laboratory surveillance reviews.
| Exposure scenario | Estimated human infection rate | Typical outcome |
|---|---|---|
| Healthy adult, household dog with kennel cough | Under 1 in 1,000 exposures | Mild cough, self-limiting |
| Veterinarian or shelter worker, routine contact | 1 to 5 per 10,000 worker-years | Mild to moderate bronchitis |
| Immunocompromised adult, sustained exposure | Up to 1 in 100 exposures | Pneumonia risk elevated |
| Infant under 6 months, household exposure | Rare but documented | Bronchiolitis possible |
| Person with cystic fibrosis | Case reports only | Colonization, exacerbation |
These figures are approximations assembled from published case reports and occupational health surveys. They are not derived from a single cohort study, and no prospective human incidence trial exists.
A 2019 review of laboratory-confirmed human Bordetella isolates found B. bronchiseptica accounted for roughly 1 to 3 percent of all Bordetella identifications in symptomatic patients. That is a small slice, but it is not zero, and it is enough to justify the standard advice that immunocompromised people should limit close contact with coughing dogs.
Human Symptoms vs. Dog Symptoms: A Side-by-Side
The clinical picture differs between species in ways that matter for recognition.
| Feature | Dogs | Humans |
|---|---|---|
| Cough onset after exposure | 2 to 10 days | 3 to 10 days |
| Cough character | Honking, often with retch | Dry, persistent, worse at night |
| Fever | Uncommon, under 102.5 F | Low grade, 99 to 101 F |
| Duration untreated | 1 to 3 weeks | 1 to 3 weeks |
| Severe complication | Pneumonia in puppies | Pneumonia in immunocompromised |
| Contagious to the other species | Yes, B. bronchiseptica only | Yes, B. bronchiseptica only |
The symptom overlap is why diagnosis in humans is often missed. A dry cough after a dog with kennel cough is frequently attributed to a cold. Clinicians rarely order a Bordetella culture unless the patient mentions animal contact or has a relevant immune condition.
Who Is at Real Risk: The Edge Cases That Change the Advice
Risk is not evenly distributed. Three groups carry most of the serious human cases.
First, immunocompromised adults. This includes people on chemotherapy, transplant recipients, and those with advanced HIV. In this group, B. bronchiseptica can progress to pneumonia, and case fatality in published reports is roughly 5 to 10 percent. That number comes from small retrospective series and is not a population risk.
Second, infants under 6 months. Their airways are narrow and their immune systems are naive. Documented cases have produced bronchiolitis requiring hospitalization. The absolute count is low, but the consequence per case is high.
Third, people with cystic fibrosis or bronchiectasis. Their airways already host chronic bacterial communities, and B. bronchiseptica can establish colonization and trigger exacerbations.
A non-obvious detail: kennel cough vaccination in dogs reduces shedding but does not eliminate it. A vaccinated dog with a mild cough can still carry and transmit B. bronchiseptica for 7 to 14 days. Owners sometimes assume vaccination means zero risk, and that assumption is wrong.
Correcting the Misconceptions
The most common misconception is that any cough after dog contact is kennel cough. In reality, the odds that a healthy adult's cough is B. bronchiseptica are low. The more likely explanations are rhinovirus, seasonal coronavirus, or allergic bronchitis.
Another misconception is that humans can catch the viral components. No human infection has been documented from canine parainfluenza virus, canine adenovirus type 2, or canine respiratory coronavirus. These viruses are species-adapted, and human airway receptors do not support efficient entry. The 2020 discovery of a canine coronavirus does not change this; it is a different virus from SARS-CoV-2 and has no human case record.
A third misconception is that kennel cough in humans requires antibiotics every time. Most healthy adults clear B. bronchiseptica without treatment. Antibiotics are indicated when symptoms persist beyond 3 weeks, when fever exceeds 101 F, or when the patient belongs to a high-risk group. The drug of choice is typically a macrolide or doxycycline, chosen because B. bronchiseptica is intrinsically resistant to many penicillins.
What to Actually Do: Practical Steps for Dog Owners and Workers
If your dog has kennel cough, the practical steps are straightforward and mostly about containment.
- Keep the dog home from daycare, parks, and training classes for 10 to 14 days after the cough starts, since shedding can persist that long.
- Wash hands with soap for 20 seconds after handling the dog, its bedding, or its food bowls.
- Avoid face-to-face contact and let the dog lick hands rather than the face during the illness.
- Have immunocompromised household members limit close contact and avoid sharing sleeping space with the dog.
- Ventilate rooms; B. bronchiseptica spreads through respiratory droplets at close range, mostly within 3 feet.
- Seek medical advice for any household member who develops a cough lasting more than 10 days, especially with fever.
For veterinary staff and shelter workers, the standard is personal protective equipment during handling of coughing dogs, plus annual review of hand hygiene protocols. Occupational surveillance data suggest the 1 to 5 per 10,000 worker-year rate drops with consistent glove and gown use.
The Timeline: From Exposure to Recovery
The time course is consistent enough to be useful for both species.
| Day | Dogs | Humans |
|---|---|---|
| Day 0 | Exposure to infected dog | Exposure to coughing dog |
| Day 2 to 10 | Cough begins, often honking | Cough begins, often dry |
| Day 3 to 7 | Peak shedding of B. bronchiseptica | Peak contagiousness |
| Day 7 to 14 | Shedding declines in vaccinated dogs | Symptoms usually improving |
| Day 14 to 21 | Cough resolves in most cases | Cough resolves in most cases |
| Day 21 to 28 | Residual shedding possible | Rare persistent cough |
| Beyond 28 days | Chronic bronchitis in rare cases | Chronic cough warrants workup |
The reconciliation point: the 10- to 14-day shedding window in dogs and the 1- to 3-week human symptom window overlap because they reflect the same underlying immune clearance timeline. Neither number is a hard cutoff, and individual variation of plus or minus 5 days is normal.
Limitations of the Evidence
The biggest gap is that no prospective study has measured human infection rates after household exposure to a coughing dog. Every incidence figure here is assembled from case reports, occupational surveys, and laboratory reviews. That means the true rate could be several times higher or lower than the estimates shown.
A second limitation is diagnostic. Most human B. bronchiseptica infections are never cultured, because the bacterium is fastidious and requires specific media. Many mild cases are simply never counted.
A third limitation is that the 10- to 100-fold lower binding efficiency figure comes from in vitro work with cell lines, not from human airways in living patients. It is a useful directional number, not a validated threshold.
What is well established is the direction of the risk: B. bronchiseptica is the only kennel cough agent with a documented human case record, transmission requires close contact, and serious outcomes concentrate in immunocompromised people, infants, and those with chronic lung disease. For a healthy adult with a coughing dog at home, the realistic risk is low, the typical illness is mild, and the sensible response is hand hygiene, a short period of separation, and medical attention if a